Testosterone Cypionate vs AndroGel: Special Populations Head-to-Head

Why Formulation Matters More in Special Populations

Most TRT comparisons treat all hypogonadal men as interchangeable. They are not. A 68-year-old with mild polycythemia vera responds very differently to weekly 200 mg cypionate than a 34-year-old with obesity. AndroGel's pharmacokinetic profile, which avoids the sharp peaks of depot injections, may benefit some groups while creating new problems for others.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "Clinicians should consider patient preference, cost, and the pharmacokinetic profile of the formulation when selecting testosterone therapy." (endocrine.org guideline) [1]

Understanding the mechanistic differences first makes every population-specific recommendation easier to follow.

Peak-Trough Dynamics

Testosterone cypionate releases over 7 to 14 days after intramuscular injection. Serum levels typically peak at 400 to 1,200 ng/dL within 24 to 72 hours, then fall to 200 to 400 ng/dL just before the next dose. That swing of several hundred nanograms per deciliter can translate to energy crashes, mood shifts, and erythrocytosis risk in susceptible men. [2]

AndroGel, applied daily to the shoulders or upper arms, produces a comparatively flat curve. A 2011 pharmacokinetic study (N=51) found that 1.62% testosterone gel maintained mean steady-state levels between 400 and 700 ng/dL with a peak-to-trough ratio of roughly 1.5:1, compared with ratios exceeding 3:1 for biweekly cypionate injections. [3]

Bioavailability and Absorption Variables

Gel absorption varies by application site, skin thickness, sweating, and washing habits. Approximately 10% of the applied dose reaches systemic circulation. Obese men with thicker subcutaneous tissue absorb transdermal testosterone less reliably, which has direct clinical relevance covered in the obesity section below. Injection bioavailability is essentially complete once the depot is formed. [4]

Older Men (Age 65 and Above)

The T-Trials consortium (NEJM 2016, N=788 men aged 65+) is the largest randomized trial of TRT in older men. Participants received testosterone gel titrated to maintain levels between 500 and 800 ng/dL. Sexual function, physical performance, and bone mineral density all showed modest but statistically significant improvements over 12 months. The sexual function domain score rose by 1.2 points on the Psychosexual Daily Questionnaire (P<0.001 vs. Placebo). [5]

Critically, the T-Trials used gel, not injections, making it the most relevant evidence base for older men. Extrapolating those results directly to cypionate injections requires caution because the peak-trough swings of injections were not studied in this cohort.

Cardiovascular Signal in Older Men

The T-Trials also reported a higher rate of coronary artery non-calcified plaque volume in the testosterone group (increase of 41 mm³ vs. 28 mm³ in placebo, P=0.003). Whether this translates to clinical events remains debated, but the FDA requires all testosterone products to carry a warning about possible increased cardiovascular risk. [6]

For older men already carrying cardiovascular risk factors, gel's flatter pharmacokinetics may reduce the transient supraphysiologic peaks that could stress the myocardium, though no head-to-head trial has proven this hypothesis in CV endpoints.

Hematocrit and Polycythemia

Men over 65 already have higher baseline hematocrit. Testosterone cypionate injections raise hematocrit more steeply than gels because the supraphysiologic peak stimulates erythropoiesis more aggressively. A 2017 meta-analysis (N=3,236, 13 RCTs) found that injectable testosterone formulations were associated with a 3-fold higher rate of polycythemia compared with transdermal formulations (OR 3.67, 95% CI 1.82 to 7.40). [7]

Hematocrit at or above 54% is a threshold for dose reduction or temporary discontinuation per Endocrine Society guidance. Older men with baseline hematocrit above 48% may be better candidates for AndroGel precisely because of this lower erythrocytosis risk.

Practical Dosing for Older Men

Starting cypionate at 75 mg every 7 days (rather than the commonly prescribed 200 mg every 14 days) reduces the peak magnitude and is increasingly preferred in geriatric TRT practice. For gel, AndroGel 1.62% at 40.5 mg/day is the typical starting point, with titration at week 14 based on morning trough levels drawn 2 to 8 hours after application. [1]

Men with Obesity (BMI 30 or Above)

Obesity complicates TRT in two ways: it reduces endogenous testosterone through aromatization of androgens to estradiol in adipose tissue, and it impairs transdermal drug absorption.

Gel Absorption in Obese Men

A pharmacokinetic sub-analysis of the AndroGel registration trials found that men with BMI above 30 required on average 20 to 25% higher gel doses to reach the same steady-state serum testosterone levels as normal-weight men. Thicker dermal layers slow diffusion, and higher rates of sweating in obese individuals may wash away gel before absorption completes. [4]

This makes cypionate injections more reliable for achieving target serum levels in men with BMI above 30. Injection delivers a fixed dose of testosterone ester into muscle regardless of skin thickness or sweat rate.

Estradiol Management

Obesity amplifies aromatase activity. Both delivery routes increase substrate for aromatization, but the cypionate injection's supraphysiologic peak provides a larger transient surge of testosterone available for conversion. Serum estradiol spikes of 60 to 80 pg/mL are more common in obese men on cypionate without aromatase inhibitor coverage. Gynecomastia rates in observational TRT registries run roughly 3 to 7% overall and are higher in men with obesity. [8]

Gel's lower peak may moderate estradiol excursions. Still, estradiol monitoring at 6 to 8 weeks after initiating either formulation is appropriate in any man with BMI above 30.

Weight and Body Composition

Neither cypionate nor AndroGel is a weight loss drug. The TRAVERSE trial (N=5,204, NEJM 2023) found that testosterone therapy modestly reduced fat mass and increased lean mass but did not produce clinically meaningful weight loss as a standalone intervention. [9] Men with obesity considering TRT should understand that GLP-1 receptor agonists such as semaglutide have a far larger effect on adiposity and may improve endogenous testosterone levels by reducing aromatase substrate.

Men with Cardiovascular Risk or Established Cardiovascular Disease

This population received the most scrutiny after the 2010 TOM (Testosterone in Older Men with Mobility Limitations) trial was stopped early because of increased cardiovascular adverse events in the testosterone arm. [10] The TRAVERSE trial (2023) subsequently provided reassurance: testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) over a median follow-up of 33 months (MACE rate 7.0% vs. 7.3%, HR 0.96, 95% CI 0.83 to 1.12). [9]

Choosing Between Formulations in CV-Risk Men

No randomized trial has directly compared cypionate injections to AndroGel on MACE endpoints. The pharmacokinetic argument for preferring gel in high-CV-risk men rests on avoiding supraphysiologic testosterone peaks, which may transiently increase platelet aggregation and blood viscosity. This remains a mechanistic hypothesis rather than a proven clinical benefit. [11]

Men with established heart failure (EF <40%) were excluded from TRAVERSE. For this group, neither formulation carries strong evidence of safety, and TRT decisions require cardiology input.

Hematocrit Monitoring Protocol

Any man with cardiovascular disease starting TRT should have hematocrit checked at baseline, 3 months, and 6 months. If hematocrit reaches 54%, pause therapy, evaluate for sleep apnea (a potent driver of secondary polycythemia), and restart at a lower dose or switch formulations. The formulation switch from cypionate to gel has anecdotally normalized hematocrit in men who chronically ran above 52% on injections, though prospective data on this specific switch are limited.

Men with Fertility Intentions

Both testosterone cypionate and AndroGel suppress the hypothalamic-pituitary-gonadal (HPG) axis. Exogenous testosterone feeds back negatively on LH and FSH secretion, reducing intratesticular testosterone and spermatogenesis. Azoospermia develops in approximately 40% of men within 4 months of starting either formulation, and oligospermia affects the majority of the remainder. [12]

Neither Formulation Is Appropriate Without Adjunct Therapy

If conception is desired, exogenous testosterone monotherapy, whether injected or applied as gel, is contraindicated as a first-line approach. Clomiphene citrate (25 to 50 mg/day or every other day) or HCG (1,000 to 2,000 IU every other day) preserves spermatogenesis while raising serum testosterone in men with secondary hypogonadism. [1]

For men who insist on TRT despite fertility goals, co-administration of HCG 500 IU every other day maintains intratesticular testosterone and has been shown to preserve sperm concentration in small RCTs. Recovery of spermatogenesis after stopping TRT takes an average of 6 to 12 months, though it may take longer in men who used cypionate at high doses for extended periods. [12]

Testicular Volume

AndroGel does not cause less testicular atrophy than cypionate injections. The HPG suppression mechanism is the same regardless of route. Any man who notices testicular atrophy or softening on either formulation should have LH, FSH, and a semen analysis performed.

Households with Women, Children, or Pregnant Partners (Transfer Risk)

AndroGel carries an FDA Black Box warning for secondary testosterone exposure through skin-to-skin contact. Children exposed to testosterone gel via contact with treated skin have developed premature pubic hair, clitoral enlargement, and advanced bone age. [13] Testosterone cypionate injections carry no secondary-transfer risk because the drug is inside muscle tissue.

Quantifying the Risk

The FDA reviewed 20 post-marketing cases of secondary exposure in children as of 2009, most involving AndroGel. The average time from gel use to symptom onset in the child was 9 months, and most cases resolved after exposure stopped. [13]

A 2010 pharmacokinetic transfer study found that 1 hour after application, rubbing the treated area against a partner's forearm for 15 minutes transferred a mean of 4.1% of the applied dose. Clothing cover, washing before contact, and application-site rotation reduce but do not eliminate transfer risk. [14]

Household-Based Formulation Selection

The following decision framework applies when a male patient lives with a female partner of reproductive age, a pregnant partner, or children under 12:

1. Testosterone cypionate injection is strongly preferred because zero transfer risk exists after the injection depot is formed.
2. If gel is chosen despite these household factors, the patient must wash the application site with soap and water before any skin contact, apply gel only to areas easily covered by clothing, and allow at least 2 hours of drying time before physical contact.
3. Any child in the household who develops unexplained pubic hair, accelerated growth, or acne should be evaluated immediately and exogenous androgen exposure should be considered in the differential.
4. Pregnant partners should avoid all contact with application sites. Testosterone is teratogenic (FDA Pregnancy Category X). [13]

Men Switching from Testosterone Cypionate to AndroGel

Switching is common when patients develop polycythemia, injection site reactions, needle aversion, or when household transfer risk becomes relevant. Several practical considerations apply.

Timing the Switch

The transition from cypionate to gel can occur at the next scheduled injection date. Starting the gel on the day the injection would have been given avoids a gap in serum testosterone coverage. No loading dose of gel is needed because steady-state AndroGel levels are achieved within 24 to 72 hours of the first application. [3]

Expect Lower Peak Levels

Men accustomed to the testosterone "feel" in the 24 to 48 hours after an injection often report feeling flat or fatigued after switching to gel. This is not a deficiency but rather the absence of supraphysiologic peaks. Serum levels should be checked 2 to 8 hours after gel application at week 14 to confirm therapeutic range (400 to 700 ng/dL target per T-Trials protocol) and dose titration should follow. [5]

Hematocrit Recovery After Switching

In men who switched from cypionate to AndroGel specifically to manage high hematocrit, observational data suggest hematocrit drops by an average of 2 to 4 percentage points over 3 to 6 months, though no randomized trial has specifically studied this endpoint. [7] Re-check hematocrit at 3 months post-switch.

Switching in the Opposite Direction (Gel to Injection)

Men switching from AndroGel to cypionate should be counseled about the peak-trough experience. Starting with a lower dose such as 75 to 100 mg weekly rather than 200 mg biweekly reduces the chance of side effects from the first peak. The first post-injection serum testosterone should be drawn at 72 hours for peak and immediately before the next injection for trough to determine individualized dosing frequency.

Side-Effect Profile Comparison Across Special Populations

| Side Effect | Testosterone Cypionate | AndroGel | |---|---|---| | Erythrocytosis | Higher risk (peak-driven) | Lower risk | | Skin irritation / contact dermatitis | Injection site bruising/pain | Application site reactions in ~5% | | Secondary transfer | None | FDA Black Box warning | | Mood fluctuation | More pronounced (peak-trough) | Milder | | Testicular atrophy | Yes (HPG suppression) | Yes (HPG suppression) | | Compliance difficulty | Needle phobia; requires administration | Daily application; easy to miss | | Cost (cash pay) | $30, $80/month | $500+/month brand; generics ~$60, $150 |

Monitoring Schedule for Both Formulations

Regardless of formulation, the Endocrine Society 2018 guideline recommends the following monitoring intervals: [1]

• Serum total testosterone at 3 months after initiation (draw at trough for injections; 2 to 8 hours post-application for gel)
• Hematocrit at 3 months and 6 months, then annually
• PSA and digital rectal exam at 3 to 6 months, then per age-appropriate prostate cancer screening guidelines
• Bone mineral density at baseline in men with osteoporosis or fracture risk; repeat at 1 to 2 years if initially low
• Lipid panel at baseline and 6 to 12 months (testosterone modestly reduces HDL-C; effect is more pronounced with injections at higher doses)

Men with sleep apnea should be treated before or concurrently with starting TRT, as testosterone worsens upper airway obstruction and secondarily raises hematocrit through nocturnal hypoxia-driven erythropoiesis. [15]